Psychosis in Parkinson’s Disease and Alzheimer’s Disease Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market

(Albany, USA) DelveInsight’s “Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast-2034″ report provides a comprehensive insight into the historical and projected epidemiology, along with market trends for Psychosis in Parkinson’s Disease and Alzheimer’s Disease in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast

Some of the key facts of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report: 

• The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market size was valued approximately USD 1,290 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Acadia’s NUPLAZID (pimavanserin) stands as the sole approved product for PDP (Parkinson’s Disease Psychosis) in the US. While it is still under investigation for ADP (Alzheimer’s Disease Psychosis), it carries a boxed warning concerning heightened mortality risks observed in elderly patients with psychosis related to dementia.
• Several medications are in various stages of development to address psychosis in Parkinson’s Disease and Alzheimer’s Disease, yet only a limited number are in advanced stages. Examples include Karuna Therapeutics’ KarXT (xanomeline-trospium), Sunovion Pharmaceuticals’ Ulotaront (SEP-363856), and Vanda Pharmaceuticals’ FANAPT (iloperidone). These are expected to be introduced to the market within the forecast period spanning from 2023 to 2034.
• The total diagnosed prevalent cases of Parkinson’s disease in the 7MM were estimated to be 2.6 million in 2023. The US accounted for approximately 45% of the total diagnosed prevalent cases of Parkinson’s disease, while EU4 and the UK accounted for 45%, and Japan for 10% in 2023. These cases are expected to increase by 2034.
• Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of Parkinson’s disease i.e. 487 thousand, follo
• In 2023, Germany contributed to roughly 18% of the total diagnosed prevalent cases of PD (Parkinson’s Disease) within the 7MM. These cases are projected to rise at a Compound Annual Growth Rate (CAGR) of 1.7% during the study period from 2020 to 2034.
• Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
•  Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
• The Parkinson’s Disease epidemiology based on gender analyzed that in the US, males diagnosed with PD are higher in number than females
• The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psychosis in Parkinson’s Disease and Alzheimer’s Disease pipeline products will significantly revolutionize the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market dynamics.

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Overview

Psychosis in Parkinson’s Disease (PD) and Alzheimer’s Disease (AD) is a challenging neuropsychiatric symptom that significantly impacts patients and caregivers. It involves hallucinations, delusions, and altered perception, worsening disease burden and reducing quality of life.

In Parkinson’s Disease, psychosis often manifests as visual hallucinations, typically mild at first but becoming more severe as the disease progresses. The primary cause is thought to be a combination of dopamine dysregulation from PD treatments and the underlying neurodegenerative process. Risk factors include older age, cognitive decline, and the use of dopaminergic medications. Management focuses on reducing or adjusting medications, and in severe cases, using antipsychotic drugs like pimavanserin that have fewer motor side effects.

In Alzheimer’s Disease, psychosis usually presents as paranoid delusions and visual or auditory hallucinations, often occurring in the middle to late stages of the disease. It is linked to the progressive degeneration of brain regions involved in perception and cognition. Treatment may involve antipsychotics, although their use is limited due to potential side effects and the risk of worsening cognitive symptoms.

Early recognition and a multidisciplinary approach are crucial in managing psychosis in PD and AD, balancing symptom control with minimizing medication side effects and addressing the needs of patients and caregivers.

Get a Free sample for the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/psychosis-in-parkinsons-and-alzheimers-disease-market

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Segmentation:

The Psychosis in Parkinson’s Disease and Alzheimer’s Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
• Prevalent Cases of Psychosis in Parkinson’s Disease and Alzheimer’s Disease by severity
• Gender-specific Prevalence of Psychosis in Parkinson’s Disease and Alzheimer’s Disease
• Diagnosed Cases of Episodic and Chronic Psychosis in Parkinson’s Disease and Alzheimer’s Disease

Download the report to understand which factors are driving Psychosis in Parkinson’s Disease and Alzheimer’s Disease epidemiology trends @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology Forecast

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psychosis in Parkinson’s Disease and Alzheimer’s Disease market or expected to get launched during the study period. The analysis covers Psychosis in Parkinson’s Disease and Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies and Key Companies

• KarXT: Karuna Therapeutics
• Ulotaront: Sunovion Pharmaceuticals
• FANAPT: Vanda PharmaceuticalsF
• ITI-1284: Intra-Cellular Therapeutics
• MK-8189: Merck Sharp & Dohme

Discover more about therapies set to grab major Psychosis in Parkinson’s Disease and Alzheimer’s Disease market share @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Treatment Landscape

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Strengths

• Increased awareness and a more in-depth understanding of the disease pathophysiology has improved diagnosis and treatment.
• The recent US FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with PD Psychosis, indicates a positive change in treatment paradigm.

Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Opportunities

• There are opportunities for pharma players to develop therapies with improved safety and tolerability profiles, effectively reducing symptoms and preventing the recurrence of Psychosis in PD and AD.
• Advancement in biomarkers for cognitive decline allows precise diagnosis and individualized treatments

Scope of the Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Companies: ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
• Key Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapies: KarXT, Ulotaront, FANAPT, ITI-1284, MK-8189, and others
• Psychosis in Parkinson’s Disease and Alzheimer’s Disease Therapeutic Assessment: Psychosis in Parkinson’s Disease and Alzheimer’s Disease current marketed and Psychosis in Parkinson’s Disease and Alzheimer’s Disease emerging therapies
• Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Dynamics: Psychosis in Parkinson’s Disease and Alzheimer’s Disease market drivers and Psychosis in Parkinson’s Disease and Alzheimer’s Disease market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement 

To know more about Psychosis in Parkinson’s Disease and Alzheimer’s Disease companies working in the treatment market, visit @ Psychosis in Parkinson’s Disease and Alzheimer’s Disease Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Report Introduction

2. Executive Summary for Psychosis in Parkinson’s Disease and Alzheimer’s Disease

3. SWOT analysis of Psychosis in Parkinson’s Disease and Alzheimer’s Disease

4. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Patient Share (%) Overview at a Glance

5. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Overview at a Glance

6. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Disease Background and Overview

7. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Psychosis in Parkinson’s Disease and Alzheimer’s Disease 

9. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Current Treatment and Medical Practices

10. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Unmet Needs

11. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Emerging Therapies

12. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Outlook

13. Country-Wise Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Analysis (2020–2034)

14. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Access and Reimbursement of Therapies

15. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Drivers

16. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Market Barriers

17.  Psychosis in Parkinson’s Disease and Alzheimer’s Disease Appendix

18. Psychosis in Parkinson’s Disease and Alzheimer’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/market-assessment-services